Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Selecting COVID-19 Convalescent Plasma for Neutralizing Antibody Potency Using a High-capacity SARS-CoV-2 Antibody Assay

E Goodhue Meyer, G Simmons, E Grebe, M Gannett, S Franz, O Darst, C Di Germanio, M Stone, P Contestable, A Prichard, R Reik, R Vassallo, P Young, MP Busch, P Williamson, LJ Dumont
doi: https://doi.org/10.1101/2020.08.31.20184895
E Goodhue Meyer
1Medical Office, Biomedical Services, American Red Cross
2Nationwide Children’s Hospital, Columbus, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Simmons
3Vitalant Research Institute, San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E Grebe
3Vitalant Research Institute, San Francisco, CA
4University of California, San Francisco, San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Gannett
5OneBlood, St. Petersburg, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Franz
3Vitalant Research Institute, San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O Darst
3Vitalant Research Institute, San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Di Germanio
3Vitalant Research Institute, San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Stone
3Vitalant Research Institute, San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Contestable
6Ortho Clinical Diagnostics, Rochester, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Prichard
5OneBlood, St. Petersburg, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Reik
5OneBlood, St. Petersburg, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Vassallo
7Vitalant, Scottsdale, AZ
8University of New Mexico School of Medicine, Albuquerque, NM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Young
1Medical Office, Biomedical Services, American Red Cross
9Vanderbilt School of Medicine, Nashville, TN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MP Busch
3Vitalant Research Institute, San Francisco, CA
4University of California, San Francisco, San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Williamson
10Creative Testing Solutions, Tempe, AZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LJ Dumont
11Vitalant Research Institute, Denver, CO
12Geisel School of Medicine at Dartmouth, Lebanon, NH
13University of Colorado School of Medicine, Aurora, CO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ldumont@vitalant.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

BACKGROUND Efficacy of COVID-19 convalescent plasma (CCP) to treat COVID-19 is hypothesized to be associated with the concentration of neutralizing antibodies (nAb) to SARS-CoV-2. High capacity serologic assays detecting binding antibodies (bAb) have been developed, nAb assays are not adaptable to high-throughput testing. We sought to determine the effectiveness of using surrogate bAb signal-to-cutoff ratios (S/CO) in predicting nAb titers using a pseudovirus reporter viral particle neutralization (RVPN) assay.

METHODS CCP donor serum collected by 3 US blood collectors was tested with a bAb assay (Ortho Clinical Diagnostics VITROS Anti-SARS-CoV-2 Total, CoV2T) and a nAb RVPN assay. CoV2T prediction effectiveness at S/CO thresholds was evaluated for RVPN nAb NT50 titers using receiver operating characteristic analysis.

RESULTS 753 CCPs were tested with median CoV2T S/CO of 71.2 and median NT50 of 527.5. Proportions of CCP donors with NT50 over various target nAb titers were 86% ≥1:80, 76% ≥1:160, and 62%≥1:320. Increasing CoV2Ts reduced the sensitivity to predict NT50 titers, while specificity to identify those below thresholds increased. As the targeted NT50 increased, the positive predictive value fell with reciprocal increase in negative predictive value. S/CO thresholds were thus less able to predict target NT50 titers.

CONCLUSION Selection of a clinically effective nAb titer will impact availability of CCP. Product release with CoV2T assay S/CO thresholds must balance the risk of releasing products below target nAb titers with the cost of false negatives. A two-step testing scheme may be optimal, with nAb testing on CoV2T samples with S/COs below thresholds.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Creative Testing Solutions Research Fund

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

1. OneBlood IRB 2. ARC and Vitalant have consents embedded in their blood donor consent that is IRB approved.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The authors have no conflict of interest related to the content in this manuscript.

Data Availability

n/a

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 02, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Selecting COVID-19 Convalescent Plasma for Neutralizing Antibody Potency Using a High-capacity SARS-CoV-2 Antibody Assay
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Selecting COVID-19 Convalescent Plasma for Neutralizing Antibody Potency Using a High-capacity SARS-CoV-2 Antibody Assay
E Goodhue Meyer, G Simmons, E Grebe, M Gannett, S Franz, O Darst, C Di Germanio, M Stone, P Contestable, A Prichard, R Reik, R Vassallo, P Young, MP Busch, P Williamson, LJ Dumont
medRxiv 2020.08.31.20184895; doi: https://doi.org/10.1101/2020.08.31.20184895
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Selecting COVID-19 Convalescent Plasma for Neutralizing Antibody Potency Using a High-capacity SARS-CoV-2 Antibody Assay
E Goodhue Meyer, G Simmons, E Grebe, M Gannett, S Franz, O Darst, C Di Germanio, M Stone, P Contestable, A Prichard, R Reik, R Vassallo, P Young, MP Busch, P Williamson, LJ Dumont
medRxiv 2020.08.31.20184895; doi: https://doi.org/10.1101/2020.08.31.20184895

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (943)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (419)
  • Epidemiology (8971)
  • Forensic Medicine (4)
  • Gastroenterology (418)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1323)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (212)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10772)
  • Intensive Care and Critical Care Medicine (571)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (221)
  • Neurology (1819)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1892)
  • Public and Global Health (4111)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (364)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)